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In experiments on the P 388 leukemia of the mouse diaqua-[l Z-bis-(fluoro- 
phenyl)ethylenediamine]platinum(II) sulfates and nitrates show a strong an- 
titumor activity irrespective of the position of the fluorine atom (ortho, mts 
or para) and of their configuration (R,R/S,S or R,S). 
Tumorhemmende [1,2-Bis(fluorphenyl)ethylendlamin]platin(II) Kom- 
plexe, 4. Teil: Biologische Priifung - I n  vivo Studien an der P 388 Leukii- 
mie 
In Versuchen an der P 388 Leukiimie der Maus zeigten Diaqua-[1,2-bis(flu- 
orphenyl)ethylendian]platin(II~~f~ und -nitrate eine stake Antitumor- 
wirkung unabhhgig von der Stellung des Fluoratoms (ortho. meta oder 
para) und ihrer Konfiguration (R,R/S,S cder R,S). 
Curpd. Confis. F-Position Counter Ion Abbrevlotion 
H D.L 2 so4 DaL-PF-PtSOQ 
D,L 3 so4 DsL-3F-PtS04 
- 27 D,L 4 so4 D,L-4F-PtS04 
- 28 WSO 2 so4 MeSO-2F-PtSOq 
- 29 *SO 3 so4 FleSO-3F-PtSOq 
- x) *so 4 so4 I"RSO-4F-PtSOq 
11. D a L  4 NO3 D,L-4F-Pt(N03)2 
- 32 Heso 4 NO3 *SO-4F-Pt ( NO3) 2 
H 2 0  OH2 
In experiments on the P 388 D, leukemia cell line we demonstrated that 
[ 1,2-bis(fluorophenyl)ethylenediamineIp~~~~~~~~~~ complexes of the same soluble diaqua[ 1,2-bis( fluorophenyl)ethylenedimine] plati- 
configuration (R,R/s,s and RSv reVctiveb) are comparabb active h e -  
spective of the position of the fluorine atom (ortho, meta or para) and the lymphocytic p 388 leukemia of the mouse. 
nature of the "leaving group" (Cr or HzO)'! However, the R,R/S,S config- 
urated compounds proved to be markedly more active than those of the R.S Results series and comparable to cisplatin". In addition, some of these compounds, 
the diaqua[ 1,2-bis(~fluorophenyl~thylenedi~ine]platinurn(II) sulfates This tumor was induced by topical administration of methylcholanthrene 
and nitrates, showed a strong inhibitory effect on the hormone dependent on the skin of DBAL? mice and established as ascites tumo?). In 1975 the 
MXT - mammary carcinoma of the mouse2'. lymphocytic P 388 leukemia of the mouse was introduced as prescreen by 
In this publication we report on the evaluation of the water 
num(n) sulfates (25 to 30) and nitrates (31 and 32) on the 
Table 1: Influence of the- Number of Transplanted P 388 Leukemia Cells on the Body 
Weight and the Median Survival Time of C&Fl Mice6) 
I 
c e l l  number body w e i g h t  ;r s ( g )  
lo5 day 1 
median day  o f  
s u r v i v a l  ( r a n g e  
10 .5  ( 1 0  - 1 2 )  
10.0 ( 1 0  - 1 4 )  
9.0 ( 8 - 1 1 )  
1'dicatedto Professor Dr. H. Heimpel, Head, Department of Medicine I11 and Chairman, Tumor Center Ulm, University of Ulm, on the occasion of his 
60th birthday. 
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Table 2: Activity of Cisplatin on the P 388 Leukemia of the Mouse Depending on the Number of Passages6’ 
a) S: solvent = polyethylene glycol 400/1,8 % NaCl solution 1:l. Cisplatin: dosage: 1.5 mglkg on day 1, 5 and 9 b) Passages: number of transplantations 
which were used in the preservation of the P 388 cell line c) Mean difference in body weights between day 5 and day 1.d T therapy; C control e) Ratio of 
median survival time of treated and untreated leukemic mice in percent 
body w e i g h t  ( g ) ‘  
day 5 - day 1 
1 - 9  
- O,? 
2 . 5  
- 3 , 3  
192 
- 2.0  
1 . 5  
- 2 , 2  
1 , o  
- 2 , l  
the National Cancer Institute - USA (NCl)4). In the therapeutic experiment, 
about lo6 leukemia cells are transplanted intraperitoneally into 8 weeks old 
female CD2F1 mice (day 0). Test substances, too, are administered intra- 
peritoneally on days 1, 5, and 9. The activity of a drug is evaluated by 
registration of the median day of survival in comparison to the solvent 
treated control. In accordance with the NCI protocol”, drugs showing a % 
TIC value 2 125 are considered antitumor active. 
The influence of the number of transplanted leukemia cells on the me- 
dian survival time of the test animals is relatively low (Table 1). In the 
range of 0.6 to 9.0 x Id cells per mouse we could not detect an accelera- 
tion of the increase of animal weights (caused by an increase of tumor 
volume). Only at the highest cell number (9 x Id) a small decrease in the 
survival time was seen. 
The experiment on the P 388 leukemia of the mouse gives also hints on 
the acute toxicity of the test compound, if the change of body weights is 
registered in the course of the trial (day 5 - day 1). A drug which produces 
a body weight reduction > 4 g is considered toxic. 
Up to the 50th in vivo-passage the P 388 leukemia does not show alter- 
ations in morphology and growth rate. Under these conditions (in vivo-pas- 
sages S 50) median survival times of mice inoculated with P 388 cells were 
comparable (cf. Table 2). Consistently, the therapeutic effect of cisplatin 
was not influenced by the number of in vivo-passages of the P 388 cells 
(Table 2). Only after >> 50 in vivo-passages the morphology of the cells 
was changed into a reticular cell like phenotype, the growth rate was dim- 
inished and the survival time of untreated animals was elongated. This 
second tumor cell type was stronger inhibited by cisplatin6). Therefore, to 
ensure the comparability of test data, we used only P 388 cells from in 
vivo-passages S 50. 
For the evaluation of the antitumor activity of [ 1,2-bis(flu- 
orophenyl)ethylenediamine]platinum(II) complexes on the 
P 388 leukemia of the mouse the dose range 1, 2, and 4 x 
lo-’ moVkg was selected as to correspond to the values 
found for 50% inhibition (ICso) of the P 388 D1 cell line 
(compare Table 1 in ref. 1) and to the highest tolerated 
single dose (about 4 x lo-’ mol/kg). The dose of 4 x 
molkg amounts to about the 10-fold of the IC50 values of 
the R,S configurated complexes and to the 100-fold of those 
of the R,R/S,S configurated analogues. In accordance with 
our results on the P 388 DI leukemia cell line the dia- 
qua[ 1,2-bis(fluorophenyI)ethylenediamine]platinum(II) sul- 
fates 25 to 30 showed a comparably strong and dose de- 
T - C d  
( g )  
median day  o f  
s u r v i v a l  ( r a n g e l  
9.0 ( 8 - 1 3 )  
21.0 ( 1 4  - 2 5 )  
10.0 ( 8 - 1 3 )  
25.0 ( 2 0  - 2 6 )  
1 0 , 5  ( 9 - 1 3 )  
2 0 , 5  ( 1 8  - 2 3 )  
1 1 , 0  ( 8 - 1 3 )  
22,5 ( 1 7  - 2 6 )  
10 .0  ( 9 - 1 3 )  
21.0 ( 9 - 2 6 )  
x T / C ‘  
233 
250  
195 
205 
210 
pendent in vivo antitumor activity in the R,R/S,S series 25 
to 27 as well as in the R,S series 28 to 30, regardless of the 
fluorine position (compare Table 3 with Table 1 in ref. 1). 
However, in contrast to our in v i m  results the related dias- 
tereomers are similarly active. As expected, the diaqua[ 1,2- 
bis(4-fluoro~henyl)ethylenediamine]platinum(II) sulfates 
27 and 30 and nitrates 31 and 32 do not differ in their 
antitumor effect (Table 3). 
The acute toxicity, evaluated from the weight difference 
day 5 - day 1, was more pronounced in the R,R/S,S series 
than in the R,S series (Table 3). This required a reduction of 
the number of injections to 2 in the leukemia mouse test 
with compounds 25 (D,L-2F-PtS04) and 26 (D,L-3F-PtS04) 
at higher dosage range. The 2-position of the fluorine atom 
seems to promote toxic side effects. Compound 25 (D.L-2F- 
PtSO4) proved to be much more toxic than all other test 
compounds. After administration of 4 x 10” mo&g 25 (day 
l), 4 out of 6 animals died on day 4 and 2 on day 8 (Table 
3). However, by transformation of 25 into its dichloroplati- 
num(I1) derivative (13 in Table 3), a strong reduction of 
acute toxicity could be achieved (compare also the com- 
ments in part “discussion”). 
Discussion 
On the basis of results of a colony forming assay (TCA) 
using the P 388 D1 leukemia cell line as test model, one 
could assume that in the dosage of 4 x mol/kg an elimi- 
nation of the tumor cells and thereby a cure is achievable 
with R,R/S,S configurated compounds but not with their 
R,S-configurated counterparts (compare Table 2 in ref. l)7). 
In contrast to our expectation, the R,R/S,S configurated dia- 
qua[ l ,2-bis(fluorophenyl)ethylenediamine]platinum(II) sul- 
fates 25 to 27 and nitrate 31 caused no cures in the mouse 
leukemia experiment, even at subtoxic dosage. 
The discrepancy between the results obtained in virro 
(TCA) and in vivo with R,R/S,S configurated diaqua[ 1,2- 
bis(fluorophenyl)ethylenediamine]platinum(II) salts 25 to 
27, 31 and 32 can be explained by a poor bioavailability 
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Table 3: Antitumor Activity of Diastereomeric Diaqua[l.2-bis(fluorophenyl)ethylenediamine]platinum(II) Sulfates and Nitrates on P 388 Leukemia of the 
C&Fl Mouse 
a Ip-administration on day I ,  5, and 9 Mean difference in body weights between day 5 and day 1 Ratio of median survival time of treated and untreated 
leukemic mice in percent 1 3  
[ 1,2-Bis(2-fluorophenyl)ethylenediamine]di~~oro~latinum(tt)'~ On day 5 no injection *) On day 9 no injection 3, Single administration on day 1; 4 animals 
died on day 4 and 2 animals on day 8 
Values belong to controls d and e Control: median survival time 9 days * Controk median survival time 10 days 
compound single median day o f  animal weight X T/CC 
dose' survival  (range) change 
d5-dlb 
[mo 1 / k g] Cgl 
D.L-2F-PtS04 
ig, 
0.L-3F-PtSO4 
(a) 
D.L-4F-PtSO4 
(27) 
meso-2F-PtS04 
(28) 
meso-3F-PtS04 
(2) 
meso-4F-PtS04 
(30) 
meso-4F-Pt (NO3I2 
(32) 
0,L-2F-PtCl2 g p h  
trJ, 
Control 
Control 
1 
2 2, 
4 3, 
1 
2 
4 
1 
2 
4 
1 
2 
4 l) 
1 
2 
4 
1 
2 
4 
1 
2 
4 
1 
2 
4 
2.4 
4.9 
9.8 
18 
20 
17 
17.5 
18 
14 
14.5 
18 
17 
23 
21 
17 
17 
22.5 
15.5 
17 
22 
17 
19 
21 
17 
18.5 
25 
19 
20.5 
17 
9 
9 
(14-20) 
14-22) 
16-17) 
16-19) 
16-19) 
6-16) 
13-18) 
( 9-19) 
(20-25) 
112-22) 
(16-19) 
115-19) 
( 19-24 1 
(14-16) 
( 5-19) 
(18-23) 
(16-18)  
(17-23 1 
(19-22) 
14-19) 
17-21 
5-26) 
17-21) 
18-22) 
11-18) 
( 6-13) 
( 8-12) 
- 1  .o 200 
-3.2 222 
0.4 189 
-1.3 194 
-4.0 200 
-1.9 156 
-0.1 161 
-1.2 200 
0.7 189 
-2.6 256 
-2.9 233 
0.4 189 
0.0 189 
-1.5 250 
1.9 172 
0.8 188 
-0.9 244 
1.5 188 
-1.9 211 
-4.1 233 
1.5 188 
0.2 206 
-1.9 278 
0.9 181 
-1.7 195 
-2.9 162 
1.6 
1.4 
under in vivo conditions. A prerequisite for a curative 
cancer chemotherapy is a drug level sufficiently high and 
persistent to cause an eradication of tumor cells which pos- 
sess an unlimited capacity of proliferation (tumor stem 
cells). Of these two requirements, the achievement of a cy- 
totoxic drug level is certainly ensured under the used ex- 
perimental conditions (intraperitoneal administration). How- 
ever, the P 388 ascites tumor seems not to be exposed to a 
cytotoxic drug concentration for a period long enough to 
eradicate the tumor stem cells. Previous cell culture expen- 
ments with compounds 27 (D,L-4F-RS04) and 31 (D,L-4F- 
Pt(NO3)2) showed that indeed long incubation times (6 h for 
a % T/C 2 90')) are necessary for total inhibition. To under- 
stand these correlations pharmacokinetic studies are re- 
quired, especially those on changes of the drug level with 
time after ip administration. 
Persumably, the irreversible binding to bionucleophils, 
mainly plasma proteins, plays a major role in the reduction 
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of bioavailability of the R,R/S,S configurated complexes. 
The inactivation process can be delayed by substitution of 
the highly reactive "leaving group" H2O by less reactive 
groups like C1- as well as by change in ligand configuration 
from R,R/S,S to R,S. 
Platinum(I1) complexes with more stable bound "leaving 
groups" like Cl' are weakly reactive prodrugs. They are 
slowly hydrolyzed into the active diaquaplatinum(I1) 
species, which are responsible for the reaction with DNA. 
This process is favored as mode of action of platinum(I1) 
complexes (compare ref. 1). The inactivation of platinum 
complexes of the prodrug type is impeded during the trans- 
port to the tumor cell. 
The alternative opportunity to delay the inactivation of 
diaqua[ 1,2-bis(fluorophenyl)ethylenediamine]platinum(II) 
salts, the change of ligand configuration from R,R/S,S to 
R,S, has the advantage of a better water solubility than that 
of dichloroplatinum(II) derivatives. The lower tendency of 
the R,S-configurated complexes to react with bionucleo- 
phils is explained by a steric shielding of Pt by the axially 
standing phenyl residue. In the R,R/S,S configurated com- 
plexes, which are thought to exist in a conformation with 
equatorially oriented phenyl residues, the Pt is more easily 
accessible for a reaction with bionucleophils. 
The lower reactivity of the two structure variants of the 
[ 1,2-bis-(fluorophenyl)ethylenediamine]platinum(II) com- 
plexes, the R,R/S,S configurated dichloroplatinum(I1) deri- 
vatives and the R,S configurated diaquaplatinum(I1) salts, 
needs of course a considerably longer interaction with the 
tumor cells to achieve comparable cytotoxic effects (com- 
pare fig. 1 and 2 in ref. 1). To obtain a curative cancer 
chemotherapy an adequate kinetic behavior of the plati- 
num(I1) complexes in the reaction with nucleophils is essen- 
tial. Too fast or too slowly reacting complexes are weakly 
active, since they are either inactivated during their trans- 
port to the tumor cell or the necessary drug level cannot be 
maintained long enough. 
In the case of the dichloroplatinum(I1) type the kinetics of 
the C1-HzO-exchange (that is the transformation of the pro- 
drug into its active form) can be accellerated by an appro- 
priate substitution in the aromatic rings (e.g. of OH in 2-po- 
sition). A hint to the practicability of this concept is the 
observation that the shift of the OH-group in the R,R/S,S 
configurated [ 1,2-bis(4-hydroxyphenyl)ethylenediamine]di- 
chloroplatinum(I1) complex to the 3- or 2-position, respec- 
tively, leads to a marked elevation of the antitumor activity 
in the P 388 leukemia mouse In an experiment 
with (R,R/S,S)-[ 1,2-bis(2-hydroxyphenyl)ethylenediamine] 
dichloroplatinum(I1) (dosage: 9 x 13.2 pmolikg, days 1 to 
9) it was even possible to cure 4 out of 6 animals"). The 
substi- tution of OH-groups also confers an increase of 
water solubility of dichloro( 1,2diphenylethylenediamine) 
platinum@) complexes, which is advantageous for their 
therapeutic use. 
In the case of the R,S configurated diaquaplatinum(I1) 
type (i.e. the therapeutically active form) the reaction with 
DNA could be improved by a diminution of the steric 
shielding of Pt. To this end one of the two phenyl rings in 
(R,S)-diaqua[ 1,2-bi~(fluorophenyl)ethylenediamine]plati- 
num(II) salts must be replaced by a smaller residue. 
A further possibility to optimize the antitumor activity of 
the (R,R/S,S)-[ 1,2-bis(fluorophenyl)ethylenediamine]plati- 
num@) Complexes is the resolution into their enantiomers. 
Since DNA is a chiral substrate, platinum complexes, con- 
taining the enantiomers of the ligand, are endowed with 
different biological activities. 
The three routes of molecule modification outlined above 
should be followed in further experiments to optimize the 
antitumor activity of [ 1,2-bis(fluorophenyl)ethylene- 
diamine] platinum(II) complexes. 
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Experimental Part 
P 388 Leukemia'2' 
The P 388 cell line was kindly provided by Dr. Bogden Laboratory of 
Experimental Oncology, E.G. and G. Bogden Laboratories, Worcester, 
Mass., USA.- Cells (105 were transplanted intraperitoneally into 7-9 
weeks old female CDZFl-mice (Zentralinstitut fiir Versuchstiere, Han- 
novec AltrominR and water ad libitum) with an average weight of 20 g. 
The test compounds were administered intraperitoneally at day 1.5, and 9 
after transplantation. The diaquaplatinum(I1) complexes were dissolved in 
bidistilled water, the dichloroplatinum(ll) complexes suspended in 50% 
polyethyleneglycol 400 (Fluca) as 0.9% NaCl solution. The median survi- 
val time of treated (6 mice/group) and control groups ( 10 mice/group) were 
determined, and the antitumor activity was expressed by % T/C. 
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